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ABSTRACT 
 
Aim:  Patients with autosomal dominant polycystic kidney disease (ADPKD) are at increased risk 
of premature mortality, morbidities and complications, which severely impair quality of life.  
However, patient-centred outcomes are not consistently reported in trials in ADPKD, which can 
limit shared decision-making. We aimed to identify outcomes important to patients and caregivers 
and the reasons for their priorities.  
Methods:  Nominal group technique was adopted involving patients with ADPKD and caregivers 
who were purposively selected from eight centres across Australia, France and the Republic of 
Korea. Participants identified, ranked and discussed outcomes for trials in ADPKD. We calculated 
an importance score (0-1) for each outcome and conducted thematic analyses.  
Results:  Across 17 groups, 154 participants (121 patients, 33 caregivers) aged 19 to 78 (mean 54.5 
years) identified 55 outcomes. The 10 highest ranked outcomes were: kidney function (importance 
score 0.36), end stage kidney disease (0.32), survival (0.21), cyst size/growth (0.20), cyst 
pain/bleeding (0.18), blood pressure (0.17), ability to work (0.16), cerebral aneurysm/stroke (0.14), 
mobility/physical function (0.12), and fatigue (0.12).  Three themes were identified: threatening 
semblance of normality, inability to control, and making sense of diverse risks.  
Conclusion:  For patients with ADPKD and their caregivers, kidney function, delayed progression 
to end stage kidney disease and survival were the highest priorities, and were focused on achieving 
normality, and maintaining control over health and lifestyle. Implementing these patient-important 
outcomes may improve the meaning and relevance of trials to inform clinical care in ADPKD. 
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INTRODUCTION  
 
Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited cystic 
kidney disease1-3.  Up to 70% of patients progress to end-stage kidney disease (ESKD) requiring 
dialysis or kidney transplantation by the age of 65 years4.  Patients with ADPKD are at an increased 
risk of premature mortality, co-morbidities and life-time complications including hepatic cysts, 
urinary tract infections, intracranial aneurysm and kidney pain, which severely impair quality of 
life. Whilst these outcomes would be expected to be critical for decision-making, they are 
infrequently and inconsistently reported across trials in ADPKD and often under-appreciated by 
treating physicians5.  
 
Despite the emphasis on empowering patients to be active partners in care and to participate in 
decision-making and research5-8, patients are seldom involved in the selection of trial outcomes. 
This is problematic given the discordance in priorities for outcomes between health professionals 
and patients with kidney disease9. Studies in ADPKD10-13 have predominantly focused on reporting 
rates of change in total kidney volume (TKV) and kidney function. Patient-reported outcomes, such 
as pain, fatigue, or anxiety14, have been largely omitted from trial reports. Patients involved in the 
development of guidelines on ADPKD identified psychosocial well-being, pain, work, and financial 
impact as important areas for support and decision-making9,15, which again are infrequently 
reported in research. 
 
The aim of this study was to systematically identify patient and caregiver priorities for outcomes in 
trials in ADPKD, and to describe the reason for their decisions. This may inform the selection of 
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patient-important outcomes for research, and thereby improve the relevance of trials for decision-
making in patients with ADPKD for improved care and outcomes. 
 
METHODS 
 
A combination of focus group and nominal group techniques16,17 was used to identify and rank 
outcomes considered important to ADPKD patients and their caregivers, and the reasons for their 
decisions.  Nominal group technique has been used to prioritise outcomes across various health 
disciplines18-20.  It encourages equal participation through minimising individual dominance and 
providing opportunity to systematically elicit the perspectives of participants18.  
 
Participant selection 
 
Patients with ADPKD and their caregivers (i.e. family members or support person involved in the 
patient’s care) aged over 18 years and able to give written informed consent were eligible. We 
recruited participants from eight centres across Australia (Brisbane, Melbourne, Sydney), France 
(Brest, La Roche-sur-Yon, Nantes, Tours), and the Republic of Korea (Seoul). We used purposive 
sampling to maximize diverse demographic (age, sex, socioeconomic status, ethnicity, and 
education) and clinical characteristics (stage of CKD:  i.e. patients not on renal replacement 
therapy, CKD stage 1-5; patients on dialysis, 5D; and patients with a kidney transplant, 5T; time 
since diagnosis, comorbidities, and complications), as was feasible. Participants had to be able to 
speak the native language (English, French, Korean) in which the groups were conducted. Our 
target was 10 participants per group for manageability and optimal group dynamics. We reimbursed 
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participants (approximately $50 USD-equivalent in local currency) for travel expenses. The Human 
Research Ethics Committee of the Western Sydney Local Health District (HREC2009/6/4.14), 
Monash Medical Centre (2010.031), Metro South Health District (17/QPAH/112), France 
(INSERM/2017) and Republic of Korea (1709-087-886) approved this study.  
 
Data Collection  
 
Each group was two hours in duration and held at a centrally located venue external to the hospital 
from June to November 2017. The focus groups were facilitated by trained moderators in native 
languages (English – A.T., T.G., Y.C.; French – B.S; Korean – Y.K.). The question guide 
(Supplementary Table 1) was adapted from those we have used to elicit patient-prioritised outcomes 
in kidney transplantation and hemodialysis24-21, and with input from the Standardised Outcomes in 
Nephrology – Polycystic Kidney Disease (SONG-PKD) Steering Group and investigators.  The 
structure of the session included: i) general discussion on living with ADPKD, and the perceived 
benefits and harms of ADPKD-related treatment; ii) individual identification to generate a group list 
of outcomes believed to be important for research, which were augmented with outcomes identified 
from trials and previous nominal groups; and, iii) individual ranking of the printed list of outcomes 
(from 1=most important to xx=least important) and group discussion of the similarities and 
differences in rankings. Participants were asked to rank individual outcomes in the order of 
importance for research in all patients with ADPKD, independent of their stage of CKD (pre-
dialysis, dialysis, transplant).  We convened focus/nominal groups until data saturation, defined as 
when no new outcomes or reasons were being identified in subsequent groups. All discussions 
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during the session were audiotaped and transcribed verbatim, and a co-facilitator recorded the 
contextual details around the discussion.  
 
Data Analysis  
 
Nominal Group Ranking 
A measure of importance for each outcome, based on the ranking results from each focus/nominal 
group, was used to prioritise the outcomes.  The steps involved in calculation of this measure were 
previously specified in the published protocol22.  The importance scores represent a summary 
measure of importance of the outcome, which incorporates the consistency of being nominated and 
the rankings given by the participants.  The importance score (IS) can be computed using the 
probabilities of each rank for each outcome (ܲ൫ ௝ܱ݅݊ ݎܽ݊݇ ݅൯, i.e., the probability of the outcome Oj 
being assigned the rank i) and weighted sum of the inverted rankingቀଵ௜ቁ: 
ܫܵ = ෍ ܲ൫ ௝ܱ݅݊ ݎܽ݊݇ ݅൯௡௥ ௢௙ ௢௨௧௖௢௠௘௦௜ୀଵ × 1݅  
 
Higher values of the score identified outcomes that were considered more important by the 
participants.  These scores were then calculated separately for a) patients and their caregivers, b) 
country, and c) stage of CKD (pre-dialysis CKD vs. CKD stage 5D vs. CKD stage 5T). The 
software packages Stata/SE version 14.0 (StataCorp. College Station, TX) and the R version 3.2.3 
(R Foundation for Statistical Computing, Vienna, Austria) were used to analyse the data.  
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Qualitative Analysis  
The transcripts were imported into HyperRESEARCH (ResearchWare Inc. www.researchware.com, 
version 3.7.2) software to facilitate qualitative data analysis. The transcripts in the original language 
were coded line by line by the facilitators (Y.C., C.S., B.S.) to identify concepts. Similar concepts 
were grouped into themes that reflected the reasons for identifying and ranking the outcomes. Using 
investigator triangulation, the preliminary findings were discussed among the research team (A.T., 
T.G., B.S., C.G., C.L., Y.C.) to ensure that themes reflected the full breadth and depth of the data.  
 
 
RESULTS 
 
Participant Characteristics 
 
Across the 17 groups, 154 participants (120 patients, 34 caregivers) attended (Table 1). The 
attendance rate was 87% and the reasons for non-attendance included work, inability to arrange 
transportation and illness. The participants were aged from 19 to 78 years (mean r standard 
deviation 54.5 r 12.3) and 67 (42%) were men. The majority of patients were pre-dialysis chronic 
kidney disease (CKD stages 1-5, n=76, 61%), followed by transplant recipients (n=31, 26%) and 
those on dialysis (n=19, 13%).  
 
Identification and ranking of outcomes 
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In total, 55 unique outcomes were identified across 17 groups (Australia (10), France (4), Republic 
of Korea (3)). The composition of the groups is provided in Supplementary Table 2.  The mean 
number of outcomes identified by each group was 33 (range, 14 to 44).  Across all participants, the 
ten highest ranked outcomes were kidney function (importance score = 0.36), end-stage kidney 
disease (ESKD, 0.32), survival (0.21), cyst size/growth (0.20), cyst pain/bleeding (0.18), blood 
pressure (0.17), ability to work (0.16), cerebral aneurysm/stroke (0.14), mobility/physical function 
(0.12), and fatigue (0.12) (Supplementary Table 3). Eight outcomes were common to all groups: 
cyst pain/bleeding, ESKD, cerebral aneurysm/stroke, survival, kidney function, cyst size/growth, 
blood pressure, and financial impact. 
 
There were some differences by country, CKD stage, and patients/caregivers. Ability to work was 
ranked highest in France (0.31), whereas kidney function was ranked highest in Australia and 
Republic of Korea (0.40, 0.37; Figure 1). Some outcomes were prioritised within the top ten 
outcomes in one country only: in Australia, cardiovascular disease (0.17) and anxiety/stress (0.12), 
in France, fatigue (0.21), and impact on family (0.12), and in Republic of Korea, infection (0.25), 
financial impact (0.20) and muscle pain (0.10) (Table S3). By CKD stage, the top three outcomes 
were: in pre-dialysis CKD, kidney function (0.36), ESKD (0.31), and cyst size/growth (0.25); in 
dialysis patients, blood pressure (0.31), kidney function (0.30), and ESKD (0.24); and in transplant 
recipients, kidney function (0.36), ESKD (0.34) and ability to work (0.27; Supplementary Figure 1).  
For patients, the top three outcomes were ESKD (0.34), kidney function (0.34) and ability to work 
(0.28), whereas for caregivers, they were kidney function (0.43), ESKD (0.33), and cyst pain/bleed 
(0.21; Figure 2).  
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Qualitative Analysis 
 
We identified three themes that reflected the reasons for the identification and prioritisation of 
outcomes: threatening semblance of normality, inability to control, and making sense of diverse 
risks. The subthemes are described below and selected quotations illustrating each theme are 
provided in Table 2. A thematic schema to illustrate the relationship among themes and outcomes is 
provided in Figure 3.   
 
Threatening semblance of normality  
 
Surviving, not thriving. Outcomes that were perceived to impair their ability to “thrive in life” were 
ranked highly by participants. For example, “fatigue” impaired their ability to find gainful 
employment and to work. They were anxious about progression to “ESKD,” as they feared dialysis 
or transplant would interfere with being able to live an “ideal life”. Participants believed that this 
could lead to helplessness and ultimately “depression”. Patients in the Republic of Korea 
commented that “surviving” was not as important because “everyone dies eventually”.  
 
Restricted from activities of daily living.  Some participants reported that symptoms, such as cyst 
pain, were relentless, limited their ability to do simple daily tasks, such as “hanging washing” or 
“grocery shopping,” and prevented their leading a “normal life”. Some outcomes attributed to cyst 
growth, including “nausea”, “indigestion” and “vomiting”, were of higher importance for patients 
who had direct experience of these symptoms. These outcomes could lead to social isolation and 
dependency on their caregivers, which made patients feel vulnerable.   
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Embarrassed by enlarged and distorted abdomen. Some female patients suffered “embarrassment 
by appearing constantly pregnant” due to their protruding abdomen from enlarged kidneys with or 
without enlarged liver. However, they explained that it was not a life-threatening outcome and, as 
such, ranked this relatively lower than outcomes that were considered important for survival.  
 
Isolated and misunderstood.  Patients at early stages of CKD felt their disease was “invisible” and 
perceived that others, including their family, could not comprehend the impact of their symptoms, 
such as “fatigue” and “depression.” One stated, “in some ways, it is better to have a broken arm.  
People can at least see the cast, they can talk about it, and they care about you. But there is nothing 
to see about our disease.”  Symptoms, such as “fatigue”, “pain” and “cognitive impairment”, which 
were not apparent to others, led to termination of employment as patients could not meet their 
employers’ expectations, and were forced to depend on disability support pensions leading to 
financial insecurity. 
 
Inability to control  
 
Impossible to cure symptoms. Patients believed they had no choice but to endure symptoms, such as 
“fatigue” and “cyst pain,”  and complications from “cyst growth” from kidneys and/or liver,  such 
as “nausea or vomiting,” for the duration of their life.  They could not envisage ever being 
symptom-free, and thus ranked the importance of these outcomes highly. Even after transplant, 
some patients still suffered from persistent cyst pain, which supported their higher ranking.  
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Rendered powerless by prognostic uncertainties. The inevitable progression to ESKD made patients 
feel “powerless” and left them wanting to “delay it as long as possible.” They had “anxiety” and 
concerns about the wellbeing of their future generations. Participants stated that life-changing or 
physically disabling complications, such as “cerebral aneurysm,” took “precedence over anything 
else”, as there were no treatments available to prevent the outcome. 
 
Visible suffering in affected family members. Some participants had seen the suffering of other 
family members with ADPKD and were anxious that they may endure the same consequences. This 
underpinned outcomes that they ranked highly: “I’ve got many members of the family with PKD 
and only one person in the family hasn’t got it.  But we haven’t had any positive outcomes.  All my 
family have died of cardiovascular disease.” Some patients were conscious that ADPKD imposed a 
“burden” on their family.  
 
Making sense of diverse risks  
 
Unpredictable and severe consequences. Patients felt planning for the future was impossible as they 
felt that they were in a “waiting game” where they did not know how quickly their kidney function 
would decline and whether they would require dialysis or a kidney transplant. Patients felt 
ambivalent about their ability to directly “influence” rate of decline in kidney function through 
lifestyle modification or medical therapy. Ongoing costs associated with continuous investigations 
to monitor status to avoid complications from ADPKD placed financial burden on participants in 
the Republic of Korea.   
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False sense of security in imperceptible sickness. Some patients felt that ADPKD did not impact on 
their “current” life situation: “I’ve never been sick from it all.  So, I’ve never felt unwell.” Thus, 
outcomes, such as diverticulitis, breathlessness, kidney stones and hernia, were ranked lower. 
 
Living with perpetual guilt. Patients felt responsible for passing on ADPKD to their younger 
generations: “to our pain is added that of seeing our children in the face of all that we have lived, 
who have seen all that we have suffered.  And knowing that they take the same path, it destroys 
even more.” Parental caregivers believed prevention of progression to ESKD would ensure a better 
future for their affected children. Diagnosis of ADPKD in children, especially sons, brought on 
challenges for parents in the Republic of Korea, as they were worried for jeopardizing future job 
opportunities due to military service exemption because of ADPKD.  
 
Fear of discrimination. Patients worried about losing their jobs and insurability: “I was diagnosed 
with it at 25 and I kept it very quiet for the longest that I possibly could and not just for employment 
purposes, but also insurances.” Patients in Republic of Korea were fearful of discrimination at work 
because the “restricted diet, abstinence from alcohol and cigarette smoking” prevented them from 
fulfilling expectations of them to participate in work and social activities. 
  
DISCUSSION 
 
For patients with ADPKD and their caregivers, clinical outcomes such as kidney function, ESKD, 
blood pressure, cerebral aneurysm/stroke, and cyst size/growth, and patient-reported outcomes 
including cyst pain/bleed, fatigue, ability to work, anxiety/stress, were of critical importance. 
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Kidney function was interpreted by patients to be a key determinant of their prognosis, specifically 
progression to ESKD. Progression to ESKD necessitating renal replacement therapy was perceived 
to severely limit the ability to live a “normal” life as there was concern that dialysis would interfere 
with their ability to work and participate in life activities as they desired. Uncertainty about their 
prognosis provoked anxiety and stress in patients, which were further exacerbated by the 
unremitting physical symptom burden, causing patients to feel powerless. These also impaired their 
capacity to work, ability to do usual activities, financial stability, and overall lifestyle. Some 
patients suffered guilt stemming from the genetic nature of ADPKD, and also had anxieties about 
their children being diagnosed with ADPKD and their prognosis.  
 
Overall, kidney function and progression to ESKD were consistently prioritised as the most 
important outcomes in patients with ADPKD and their caregivers. Stability in kidney function 
provided reassurance to patients, whereas a decline in function provoked anxiety because their 
prognosis was perceived to be beyond their control. Whilst the importance of progressing to ESKD 
is undisputed5,15, trials in ADPKD have largely focused on measuring kidney function, often 
reported as change in estimated glomerular filtration rate (eGFR) and TKV, and have not explicitly 
examined progression to ESKD10,11,23.  This may relate to the long natural history of the disease, 
with a lack of a reliable biomarker to assess progression to ESKD in early stage CKD patients with 
ADPKD who are typically eligible to be enrolled in clinical trials10,11,23,24.  Further, interventions in 
far advanced CKD when kidneys are large and presumably fibrotic, where ESKD is more likely, are 
thought to be less likely to be successful.  
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Patient-reported outcomes, such as pain and fatigue, ranked high in importance because they 
relentless and constantly reminded patients of their condition. These often unrelenting symptoms 
impaired their lifestyle, usual activities, and vocational potential, and threatened their financial 
security. Subsequently, this had a detrimental impact on their mental well-being, and they felt guilty 
in having to remain dependent on their family. Some patients reported being depressed from social 
isolation and experienced a loss of self-confidence from incapacity to work with deterioration in 
financial status. The lack of such patient-reported outcomes in trials was recently identified as a 
major gap in ADPKD trials at the Kidney Disease: Improving Global Outcomes (KDIGO) 
controversies conference15.  Recently, a new health-related quality of life instrument for patients 
with ADPKD (ADPKD-IS) was developed, which consists of 14 items that measure three 
conceptual domains: physical, emotional and fatigue, and four additional questions on guilt, sleep, 
size/shape of abdomen, and urinary frequency/urgency25. This measure includes outcomes 
identified in our study, including ability to work, life participation, fatigue, physical function, pain, 
anxiety, depression, gastrointestinal symptoms (early satiety), sleep, appearance and urine output25. 
However, impact on family, financial impact, and cognition are not included in the ADPKD-IS.  
 
In our study, there were notable differences in the ranking of outcomes across countries, stages of 
CKD, and patients versus caregivers. Ability to work was ranked highest in France, whereas 
financial impact was ranked in the top ten only in the Republic of Korea. Although the proportion 
of participants in fulltime/part time employment in France (40%) was lower than Republic of Korea 
(69%), it was comparable to Australia (40%). In France, ability to work was often considered 
synonymous to health, supported by findings of a national survey, which showed that the majority 
of French loved their work (76%) and/or were proud of it (56%)26.  For patients/caregivers in the 
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Republic of Korea, the ongoing health care costs incurred a substantive financial burden owing to 
perceived insufficient government funded support and some investigations including genetic test for 
ADPKD are not covered by the National Health Insurance scheme. Of note, progression to ESKD 
was ranked lower in the Republic of Korea (0.18) compared to other countries (Australia: 0.38, 
France: 0.27), which could be because the majority were pre-dialysis CKD patients (83%). Regional 
differences in how patient-reported outcomes were prioritized across focus groups conducted in 
United States, Europe and Japan were also observed by ADPKD-IS investigators, reinforcing the 
importance of capturing diverse population25.  These results are not surprising given the 
heterogeneous nature of ADPKD with variable symptom burden, and the potential variability in 
values attached to outcomes by country and cultures.  Patients also prioritised outcomes based on 
direct relevance to their current stage of CKD. For example, patients on dialysis ranked pruritus and 
blood pressure more importantly. Patients gave higher priority to outcomes related to physical 
function (mobility/physical strength, fatigue) and psychosocial impact (ability to work, impact on 
family) that hindered ability to participate in life, whereas caregivers were concerned about patients 
suffering from symptom burden (cyst pain/bleed; cyst size/growth) and life threatening outcomes 
(cardiovascular disease).  
 
We recruited patients with ADPKD and their caregivers from three countries to capture diverse 
cultural backgrounds and healthcare systems.  A combined quantitative and qualitative 
methodology based on nominal group technique provided comprehensive data about their priorities, 
attitudes and beliefs with regards to ADPKD outcomes. However, there are some potential 
limitations. Most patients were in the pre-dialysis stage of CKD (61%) with the highest proportion 
of pre-dialysis CKD patients amongst Korean participants (83%). All focus groups took place in 
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high-income countries, and the majority of participants were older than 40 years of age. Therefore, 
transferability of the findings beyond these populations is uncertain.  
 
International guidelines on ADPKD emphasize the need to deliver patient-centred care, which 
involves shared decision-making9,15.  This may be facilitated by consistent reporting of outcomes 
that are meaningful and relevant to patients across trials in ADPKD. The findings from the current 
study will directly inform the development of a core outcome set for trials in ADPKD incorporating 
priorities of all stakeholders including patients, based on the Standardized Outcomes in Nephrology 
(SONG) initiative, to enable consistent measurement and reporting of relevant and important 
outcomes in trials22.  
 
Patients with ADPKD and their caregivers gave highest priority to clinical outcomes (such as 
kidney function, ESKD, and cyst size/growth), as well as symptoms, psychosocial and lifestyle 
impacts (cyst pain, fatigue, ability to work, and anxiety/stress). These outcomes were highly 
prioritised because they were perceived to substantively diminish their sense of control and 
normality, and ability to achieve the life goals they valued. Yet, many of these outcomes are not 
universally reported in trials in ADPKD10,11,23,24.  Consistent reporting of outcomes that are most 
relevant and meaningful to patients with ADPKD is needed to empower patients and clinicians for 
shared decision-making. 
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 Table 1.  Participant Demographic Characteristics.  
 
Characteristic Australia 
n=85  
(%) 
France  
n=40 
(%) 
Republic 
of Korea 
n=29 
(%) 
All 
participants 
n=154 
(%) 
Participant Status 
Patient 
Caregiver 
 
61 (72) 
24 (28) 
 
36 (90) 
4 (10) 
 
24 (83) 
5 (17) 
 
121 (79) 
33 (21) 
Male 35 (41) 17 (43) 12 (41) 64 (42) 
Age (years) 
18-39  
40-59  
60-79  
 
16 (19) 
34 (40) 
35 (41) 
 
2 (5) 
18 (45) 
20 (50) 
 
3 (10) 
20 (69) 
6 (21) 
 
21 (13) 
72 (47) 
61 (40) 
Highest level of education^  
Primary school: grade 6 
Secondary school: grade 10  
Secondary school: grade 12 
Tertiary: certificate/diploma 
Tertiary: university degree 
 
4 (5) 
18 (22) 
7 (8) 
25 (30) 
29 (35) 
 
2 (5) 
8 (20) 
14 (35) 
4 (10) 
12 (30) 
 
1 (4) 
2 (7) 
5 (17) 
0 (0) 
21 (72) 
 
7 (5) 
28 (18) 
26 (17) 
29 (19) 
62 (41) 
Employment status 
Full-time 
Part-time or casual 
Not employed 
Retired 
Other (e.g. income protection 
insurance) 
 
21 (25) 
17 (20) 
11 (13) 
28 (33) 
8 (9) 
 
12 (30) 
4 (10) 
0 (0) 
19 (47) 
5 (13) 
 
17 (59) 
3 (10) 
4 (14) 
2 (7) 
3 (10) 
 
50 (32) 
24 (16) 
15 (10) 
49 (32) 
16 (10) 
Ethnicity  
White 
Asian 
Other 
 
72 (85) 
7 (8) 
6 (7) 
 
40 (100) 
0 (0) 
0 (0) 
 
0 (0) 
29 (100) 
0 (0) 
 
112 (73) 
36 (23) 
6 (4) 
CKD Stage** 
Pre-dialysis 
Dialysis 
Transplantation  
 
34 (56) 
11 (18) 
16 (26) 
 
20 (55) 
2 (6) 
14 (39) 
 
20 (83) 
3 (13) 
1 (4) 
 
74 (61) 
16 (13) 
31 (26) 
Age at Diagnosis^** 
0-20 y 
21-40 y 
 
10 (17) 
35 (57) 
 
6 (17) 
21 (58) 
 
3 (13) 
14 (58) 
 
19 (16) 
70 (58) 
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41-60 y 
>60 y 
13 (21) 
3 (5) 
7 (19) 
2 (6) 
6 (25) 
1 (4) 
26 (21) 
6 (5) 
^missing data from 2 participants; ** patient-only (n=61; n=31; n=24).Abbreviations: ADPKD, 
autosomal dominant polycystic kidney disease; CKD, chronic kidney disease. 
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Table 2.  Select participant quotations for each theme reflecting the reasons for the ranking of 
outcomes. 
Subthemes Quotations 
 
 
 
Surviving, not 
thriving 
 
 
 
 
 
 
 
 
 
 
 
 
 
Restricted from 
activities of daily 
living 
 
 
 
 
 
 
 
 
Embarrassed by 
enlarged and 
distorted 
abdomen 
 
 
 
 
 
 
 
Threatening semblance of normality 
 
“Just have a normal life. See when you have polycystic kidneys, you don’t have a 
normal life.  What you eat, what you drink, how you sleep, no exercise, constant 
pain, the effect on your family.  Because when you start out it’s ok, but as the 
years go on, you become more debilitating, and all you’re doing is surviving, not 
living.”  (FG7, patient) 
“Depression he battled because he can’t – he was a workaholic all his life and 
now he can’t do anything.  So he gets really depressed about it.” (FG1, 
caregiver) 
 “I’ve actually ended up having to leave work at age 44 and I had intended to 
work until 60, so having to manage on a small pension was very hard.” (FG5, 
patient) 
 “Everyone dies eventually, so I don’t think death is very important.” (FG15, 
patient)  
 
 
“If you can’t push a trolley or you can’t access the world in the way that you 
want to access it that has implications for your mental health and your just 
general wellbeing.” (FG5, patient) 
“I can’t go out for meals at night, as the cysts in my liver and kidney are getting 
bigger and bigger there’s no room and it’s pushing up my stomach.  So if I go 
out with friends at night I usually end up vomiting.” (FG5, patient) 
“There are days when I will sit and have a sook to myself… why is this 
happening? Why? I just want a normal day.. pain-free day… it all comes back to 
PKD.”  (FG6, patient) 
  
 
“I’m not going to worry about going to hospital because I know that’s going to 
happen but if you’re going to come up with solutions it’s solutions around 
reducing the size of the growth or the size of the kidneys, it affects everyone, the 
clothes you wear, the way people perceive you, other people’s perception.” 
(FG2, patient) 
 “I’m embarrassed by perceptions of others who must think I am too old to be 
pregnant.” (FG16, patient) 
“I can’t find clothes that fit me properly because I am thin except around the 
abdomen.  I have to wear pants with elastic band, but really you can’t wear such 
clothes to work….. also, when I get on the train, people ask me to take their seat 
because they think I’m pregnant.  I don’t know how to respond, I don’t want to 
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Isolated and 
misunderstood 
 
 
 
explain every time that I am not pregnant but then don’t want to say I am 
pregnant.” (FG16, patient) 
 
 
“I left my job in a way because I wasn’t thinking right anymore.  ……. My 
ability, I really felt, went down and I started getting embarrassed in class…. I 
lost it.” (FG4, patient) 
 “Probably depression and pain is probably the worst for me, because I had a, 
just thought I was, you know, making it all up basically.” (FG8, patient) 
“Sometimes from the family.. who doesn’t understand.  Because our sickness if 
invisible.  In some way, it is better to have a broken arm.  People can at least see 
the cast, they can talk about it.  They care about you.  But there is nothing to see 
about our disease.” (FG13, patient) 
  
 
 
Impossible to 
cure symptoms  
 
 
 
 
 
 
 
 
Rendered 
powerless by 
prognostic 
uncertainties 
 
 
 
 
 
 
 
 
 
Visible suffering 
in affected 
family members 
Inability to control 
 
“You can’t handle anything if you’re tired.  You just don’t cope.” (FG1, patient) 
“It impacts so much on your general comfort in life and that’s huge.  If you’re 
not comfortable, if you’re in pain or discomfort or just feeling full it really 
impacts on your life every moment of the day and night.” (FG5, patient) 
“I’ve had a transplant, but PKD still affected me because my liver is full of cysts. 
I’ve got a transplanted kidney and there’s no issues, it gets bigger issues because 
your liver, you still get the pain and whatever is related to the cysts. It still stays 
with you, doesn’t go away.” (FG7, patient)  
 
 
“Well, just a fact of life, I think.  What can you do about it?  I guess, it just hopes 
delay it [decline in kidney function] as long as possible.  You’ve really got no 
power over it.” (FG5, patient) 
“she’s [daughter] got a cerebral aneurysm…. And that’s quite hard to live with, 
because it takes precedence over anything else, even the kidneys… there’s really 
not much that anyone can do.” (FG5, patient) 
“I just think having children, my own sons, obviously that’s the first thing that 
comes to my mind, you know.  Are they, how, are they going to have a normal 
life and live to become grandparents themselves, that’s my worry.  The first thing 
that comes to mind is, you know, how long will they survive for” (FG10, 
caregiver) 
 
 
“I’ve got many members of the family with PKD and only one person in the 
family hasn’t got it.  But we haven’t had any positive outcomes.  All my family 
have died of cardiovascular disease.” (FG5, patient)  
 “My grandfather and my father both died young.  So, I pretty much assumed I 
wasn’t going to live too long either.” (FG1, patient)  
“It’s been fear for me, seeing what my mother went through and the age that her 
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kidneys failed, and reaching, or just before reaching that same age, yeah, just 
the fear factor of, yeah, everything she went through.” (FG3, patient) 
 
 
 
Unpredictable 
and severe 
consequences 
 
 
 
 
 
 
 
 
False sense of 
security in 
imperceptible 
sickness  
 
 
 
 
Living with 
perpetual guilt 
 
 
 
 
 
 
 
 
 
Fear of 
discrimination  
Making sense of diverse risks 
 
 “I guess, from diagnosis it’s a waiting game.  Now knowing when, how fast or 
when your kidneys are going to deteriorate.” (FG5, patient) 
“It’s also very difficult living your life from blood test to blood test.  The closer 
you get to needing some sort of kidney replacement therapy, you know, is it 
going to be this time, you know, every time you have the test.  And that’s quite 
stressful just wondering is it going to be this time.” (FG5, patient)  
 “A sword of Damocles all the time.  I’m scared all the time of what’s going to 
happen… and for me, it’s really a sword that will hit, we do not know when, we 
do not know where, but we know it will hit.  It will hit us, it will hit for others.” 
(FG14, patient) 
 
“I’ve never been sick from it all.  So, I’ve never felt unwell.” (FG1, patient) 
 “I’d never felt ill or anything, and so everything came back pretty normal except 
my kidney functions.” (FG4, patient) 
“I never felt sick.  Yes I’d be going to hospital when I had a cyst burst or I’d 
bleed and got pain, but the rest of the time I was working full time and 
commuting to and from work, going to the gym, exercising and everything, I 
mean, it wasn’t making me sick.” (FG7, patient) 
 
 “The first thing that comes to me is guilt.  When I look at my three children and 
then look at my grandchildren and think which one of you.  And, yeah, that’s 
pretty rotten to know that you’re responsible for… not that it’s any fault of yours, 
but handing it down the line.” (FG5, patient) 
“I was thinking of point of view of knowing two of my children have got it so 
younger generation I would like anything like this to happen that would minimize 
the develop of end stage kidney failure…” (FG6, patient) 
 “It threatens our children. And that’s the hardest thing.  To be sick, I am used 
to.  But to know that.. it’s going to happen to my son… that’s unbearable.  
Because we are responsible.” (FG14, patient)  
 
“I was diagnosed with it at 25 and I kept it very quiet for the longest that I 
possibly could and not just for employment purposes but also insurances, things 
like that, life insurance they won’t touch you.” (FG2, patient)  
 “For men, when you work, you become fearful of attending company workshops 
or dinners.  Because when you go, you are expected to drink alcohol, smoke 
cigarette, eat meat…. And these fears [of adverse health impact] negatively 
affect your ability to work freely.” (FG15, patient) 
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Figure Legends 
Figure 1. Importance score for outcomes identified according to country status 
Figure 2. Importance score for outcomes identified according to patient status. 
Figure 3. Thematic Schema.  
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